Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob M Rowe

Showing results (131-140 of 275) with videos related to

Pageof 28
Sort By:
Cancer|January 19, 2012
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Irit Avivi, Jacob M Rowe, et al.
British Journal of Haematology|December 25, 2024
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot studyChezi Ganzel, Avraham Frisch, Ofir Wolach, et al.
Leukemia & Lymphoma|June 2, 2020
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemiaStephen A Strickland, Xin Victoria Wang, Jan Cerny, et al.
Cancer|July 15, 2010
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology GroupJacob M Rowe, Haesook T Kim, Peter A Cassileth, et al.
Experimental Hematology|February 6, 2014
Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesisRoni Shouval, Liran I Shlush, Shlomit Yehudai-Resheff, et al.
Blood|April 19, 2012
An activating intragenic deletion in NOTCH1 in human T-ALLJ Erika Haydu, Kim De Keersmaecker, Mary Kaye Duff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2004
Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology GroupMartin S Tallman, Haesook T Kim, Elisabeth Paietta, et al.
Experimental Hematology|December 24, 2021
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatmentAriella Tvito, Aaron Ronson, Renan Ghosheh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2016
Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to TherapyOfrat Beyar-Katz, Etty Kruzel Davila, Tsila Zuckerman, et al.
Blood|July 24, 2010
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903Ruben A Mesa, Xiaopan Yao, Larry D Cripe, et al.
Pageof 28

Showing results (131-140 of 275) with videos related to

Sort By:
Pageof 28
Cancer|January 19, 2012
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Irit Avivi, Jacob M Rowe, et al.
British Journal of Haematology|December 25, 2024
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot studyChezi Ganzel, Avraham Frisch, Ofir Wolach, et al.
Leukemia & Lymphoma|June 2, 2020
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemiaStephen A Strickland, Xin Victoria Wang, Jan Cerny, et al.
Cancer|July 15, 2010
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology GroupJacob M Rowe, Haesook T Kim, Peter A Cassileth, et al.
Experimental Hematology|February 6, 2014
Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesisRoni Shouval, Liran I Shlush, Shlomit Yehudai-Resheff, et al.
Blood|April 19, 2012
An activating intragenic deletion in NOTCH1 in human T-ALLJ Erika Haydu, Kim De Keersmaecker, Mary Kaye Duff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2004
Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology GroupMartin S Tallman, Haesook T Kim, Elisabeth Paietta, et al.
Experimental Hematology|December 24, 2021
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatmentAriella Tvito, Aaron Ronson, Renan Ghosheh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2016
Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to TherapyOfrat Beyar-Katz, Etty Kruzel Davila, Tsila Zuckerman, et al.
Blood|July 24, 2010
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903Ruben A Mesa, Xiaopan Yao, Larry D Cripe, et al.
Pageof 28